Celgene helped seal its reputation as one of the boldest dealmakers in biotech today, putting up $177.25 million in an upfront fee and equity stake while committing to more than $3 billion in milestones to partner on a slate of cancer stem cell programs in development at OncoMed.
This year's examination of our top 5 stories of the year says a lot about what works when you're creating a presence on the world wide web and how it can also deliver super-sized audiences on some odd bits of work.
Thursday night the biotech company offloaded the product, and its mesenchymal stem cell platform in regenerative medicine, to Australia's Mesoblast for $50 million in near-term cash and stock and up to $50 million more in milestones.
After more than a year of not-so-secret negotiations, Geron has finally auctioned off its long-stalled embryonic stem cell pipeline, handing it over to a newly created BioTime subsidiary in exchange for shares.
Cancer-fighting T cells figure prominently in the experimental immunotherapies being developed these days. And now researchers say they have found a way to efficiently recruit a mass of these immune-system warriors in the fight against cancer and infectious diseases.
For the first time, we have reached the point where clinical data on stem cell therapeutics can be reported, and these early results have been promising, offering a first glimpse into the full potential of stem cell treatments.
The biotech says it will use the cash to "accelerate and expand its stem cell technology-based drug rescue programs."
Shares of Italy's Gentium plunged more than 40% this morning after the biotech announced a fresh round of woes with regulators--this time in Europe--for its vascular drug defibrotide.
The FDA awarded orphan drug status to Lentigen's brain tumor stem cell treatment that protects healthy cells from a particularly toxic cancer drug. The orphan drug designation, an incentive for companies developing treatments for rare diseases, allows for 7 years of market exclusivity.
Pluristem Therapeutics ($PTSI) fired off a press release yesterday demanding corrections to a Bloomberg article this week about the company's stock sale that followed the undisclosed death of a patient who got the biotech's experimental stem cell therapy. Below the demand, in its statement, the company let loose another important detail: That not one, but two of three patients who received its therapy under compassionate use guidelines died after treatment.